Tragara takes S*BIO's fourth molecule into the clinic
This article was originally published in Scrip
Executive Summary
Licensee Tragara Pharmaceuticals has begun a Phase I development programme for what is S*BIO's fourth molecule to enter clinical trials since the private Singapore venture was set up in 2000.